Share
Journal Information
Special content about coronavirus SARS-CoV-2 (COVID-19) in Endocrinología y Nutrición (English Edition)
Direct health care costs in patients with type 2 diabetes mellitus six months after starting insulin treatment in Spain: The INSTIGATE Study
María Costi, Helen Smith, Jesús Reviriego, Conxa Castell, Alberto Goday, Tatiana Dilla
10.1016/S2173-5093(11)70060-5
Endocrinol Nutr 2011;58:274-82
Full text access
Recommendations for the pharmacological treatment of hyperglycemia in type 2 diabetes
Edelmiro Menéndez Torre, Francisco Javier Lafita Tejedor, Sara Artola Menéndez, Jesús Millán Núñez-Cortés, Ángeles Alonso García, Manuel Puig Domingo, José Ramón García Solans, Fernando Álvarez Guisasola, Javier García Alegría, Javier Mediavilla Bravo, Carlos Miranda Fernández-Santos, Ramón Romero González
10.1016/S2173-5093(11)70022-8
Endocrinol Nutr 2011;58:112-20
Full text access
Special content about COVID-19
- Gut microbiota and type 2 diabetes mellitus
- Healthcare costs of people with type 2 diabetes mellitus in the Basque Country (Spain)
- Use of healthcare resources and costs associated to the start of treatment with injectable drugs in patients with type 2 diabetes mellitus
- Efficacy and safety of empagliflozin in combination with other oral hypoglycemic agents in patients with type 2 diabetes mellitus
Publication History